Publications

Phase 1B/2A published trial results
Publication Title: Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis.
JournalMultiple Sclerosis Journal - Experimental, Translational and Clinical January - December 2015 vol. 1 2055217315583385
A myeloid directed immune therapy for secondary progressive
Poster Title: A myeloid directed immune therapy for secondary progressive MS, MIS416 modulates homeostatic CNS leucocyte trafficking
Meeting: Keystone Symposia - Neuroinflammation in Diseases of the Central Nervous System
MIS416 Enhances Negative Regulators of Inflammation
Poster Title: Innate Immune Modulator MIS416 Enhances Systemic Levels of Negative Regulators of Inflammation in Phase 2a Clinical Trial Plasma Samples
Meeting: ECTRIMS 2014
Targeting Innate Receptors with MIS416 in a model of MS
Publication Title: Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis
Journal: PLoS ONE 9(1): e87712. doi:10.1371/journal.pone.0087712
MIS416, a non-toxic microparticle adjuvant
Publication Title: MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyldipeptide and bacterial DNA promotes cross-priming and Th1 immunity.
Journal: Vaccine. 2011 Jan 10;29(3):545-57. doi: 10.1016/j.vaccine.2010.10.040. Epub 2010 Oct 27.